ZZPZH(SH:600436) Zhong Zheng Wang·2026-02-12 05:29Core Viewpoint - The controlling shareholder of Pianzaihuang, Zhangzhou Jiulongjiang Group, has completed a share buyback, reflecting confidence in the company's long-term value and development potential [1][2]. Group 1: Shareholder Actions - Zhangzhou Jiulongjiang Group announced a plan to increase its stake in Pianzaihuang from February 1 to July 31, 2026, with a total investment of no less than 300 million yuan and no more than 500 million yuan [1]. - Following the buyback, the shareholding of Zhangzhou Jiulongjiang Group increased from 50.97% to 51.04%, with the number of shares rising from 30,752,264.43 shares to 30,795,774.43 shares [1]. Group 2: R&D and Innovation - Pianzaihuang has been actively investing in R&D, with a pipeline that includes 6 traditional Chinese medicine innovative drugs, 6 chemical drugs, 6 classic ancient formulas, and 1 innovative biological product [2]. - The company has 10 innovative drugs entering critical clinical stages, including PZH2108 for cancer pain, PZH2113 for anti-tumor treatment, and PZH2107 for fibromyalgia, all of which have completed the first subject enrollment in their respective clinical trials [2]. - The ongoing R&D efforts are expected to enhance the company's position in the traditional Chinese medicine sector and contribute to the innovative development of the industry [2].